Literature DB >> 12431658

Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients.

M G Kiehl1, K Schäfer-Eckart, M Kröger, M Bornhäuser, N Basara, I W Blau, J Kienast, A A Fauser, G Ehninger, V W Armstrong, M Shipkova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12431658     DOI： 10.1016/s0041-1345(02)03489-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

Review 1.  Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Authors:  Kentaro Minagawa; Motohiro Yamamori; Yoshio Katayama; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

Review 2.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

3.  Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Authors:  Saurabh Chhabra; Ying Liu; Michael T Hemmer; Luciano Costa; Joseph A Pidala; Daniel R Couriel; Amin M Alousi; Navneet S Majhail; Robert K Stuart; Dennis Kim; Olle Ringden; Alvaro Urbano-Ispizua; Ayman Saad; Bipin N Savani; Brenda Cooper; David I Marks; Gerard Socie; Harry C Schouten; Helene Schoemans; Hisham Abdel-Azim; Jean Yared; Jean-Yves Cahn; John Wagner; Joseph H Antin; Leo F Verdonck; Leslie Lehmann; Mahmoud D Aljurf; Margaret L MacMillan; Mark R Litzow; Melhem M Solh; Muna Qayed; Peiman Hematti; Rammurti T Kamble; Ravi Vij; Robert J Hayashi; Robert P Gale; Rodrigo Martino; Sachiko Seo; Shahrukh K Hashmi; Taiga Nishihori; Takanori Teshima; Usama Gergis; Yoshihiro Inamoto; Stephen R Spellman; Mukta Arora; Betty K Hamilton
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-25       Impact factor: 5.742

4.  Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.

Authors:  Atsuo Okamura; Motohiro Yamamori; Manabu Shimoyama; Yuko Kawano; Hiroki Kawano; Yuriko Kawamori; Shinichiro Nishikawa; Kentaro Minagawa; Kimikazu Yakushijin; Yoshio Katayama; Toshiyuki Sakaeda; Midori Hirai; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2008-05-14       Impact factor: 2.490

5.  Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.

Authors:  Franck Saint-Marcoux; Bernard Royer; Jean Debord; Fabrice Larosa; Faezeh Legrand; Eric Deconinck; Jean-Pierre Kantelip; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.

Authors:  L Johnston; M Florek; R Armstrong; J S McCune; S Arai; J Brown; G Laport; R Lowsky; D Miklos; J Shizuru; K Sheehan; P Lavori; R Negrin
Journal:  Bone Marrow Transplant       Date:  2011-05-09       Impact factor: 5.483
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.